The table below is a review of notable updates that occurred in April 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
First-line treatment selection in HER2-mutant NSCLC balances route of administration, efficacy data by mutation subtype, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results